{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:55:36Z","timestamp":1783407336876,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00277-020-04233-w","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T02:03:05Z","timestamp":1598925785000},"page":"2497-2505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0299-7273","authenticated-orcid":false,"given":"Rishi J.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufaddal","family":"Mahesri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Globe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mutebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Achebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"issue":"4 Suppl","key":"4233_CR1","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","volume":"38","author":"KL Hassell","year":"2010","unstructured":"Hassell KL (2010) Population estimates of sickle cell disease in the U.S. Am J Prev Med 38(4 Suppl):S512\u2013S521. https:\/\/doi.org\/10.1016\/j.amepre.2009.12.022","journal-title":"Am J Prev Med"},{"issue":"3","key":"4233_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/gim.2012.128","volume":"15","author":"Y Wang","year":"2013","unstructured":"Wang Y, Kennedy J, Caggana M, Zimmerman R, Thomas S, Berninger J, Harris K, Green NS, Oyeku S, Hulihan M, Grant AM, Grosse SD (2013) Sickle cell disease incidence among newborns in New York State by maternal race\/ethnicity and nativity. Genet Med 15(3):222\u2013228. https:\/\/doi.org\/10.1038\/gim.2012.128","journal-title":"Genet Med"},{"issue":"7","key":"4233_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3324\/haematol.10937","volume":"92","author":"P Telfer","year":"2007","unstructured":"Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H, Smalling B, Amos R, Stephens A, Rogers D, Kirkham F (2007) Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 92(7):905\u2013912","journal-title":"Haematologica"},{"issue":"17","key":"4233_CR4","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","volume":"115","author":"CT Quinn","year":"2010","unstructured":"Quinn CT, Rogers ZR, McCavit TL, Buchanan GR (2010) Improved survival of children and adolescents with sickle cell disease. Blood 115(17):3447\u20133452. https:\/\/doi.org\/10.1182\/blood-2009-07-233700","journal-title":"Blood"},{"issue":"11","key":"4233_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0027-9684(15)30727-6","volume":"102","author":"N Artz","year":"2010","unstructured":"Artz N, Whelan C, Feehan S (2010) Caring for the adult with sickle cell disease: results of a multidisciplinary pilot program. J Natl Med Assoc 102(11):1009\u20131016","journal-title":"J Natl Med Assoc"},{"issue":"23","key":"4233_CR6","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","volume":"330","author":"OS Platt","year":"1994","unstructured":"Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330(23):1639\u20131644. https:\/\/doi.org\/10.1056\/NEJM199406093302303","journal-title":"N Engl J Med"},{"issue":"6","key":"4233_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","volume":"84","author":"DR Powars","year":"2005","unstructured":"Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C (2005) Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 84(6):363\u2013376","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"4233_CR8","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ajh.23683","volume":"89","author":"H Elmariah","year":"2014","unstructured":"Elmariah H, Garrett ME, De Castro LM, Jonassaint JC, Ataga KI, Eckman JR, Ashley-Koch AE, Telen MJ (2014) Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol 89(5):530\u2013535","journal-title":"Am J Hematol"},{"issue":"20","key":"4233_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","volume":"332","author":"S Charache","year":"1995","unstructured":"Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR, Anemia IotMSoHiSC (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332(20):1317\u20131322","journal-title":"N Engl J Med"},{"issue":"9778","key":"4233_CR10","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","volume":"377","author":"WC Wang","year":"2011","unstructured":"Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 377(9778):1663\u20131672","journal-title":"Lancet"},{"issue":"3","key":"4233_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","volume":"379","author":"Y Niihara","year":"2018","unstructured":"Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I (2018) A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med 379(3):226\u2013235","journal-title":"N Engl J Med"},{"key":"4233_CR12","doi-asserted-by":"publisher","unstructured":"Steinberg MH (2020) Treating sickle cell anemia: a new era dawns. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.25724","DOI":"10.1002\/ajh.25724"},{"key":"4233_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1001\/jama.2019.11419","volume":"322","author":"EJ Benz Jr","year":"2019","unstructured":"Benz EJ Jr, Mondoro TH, Gibbons GH (2019) Accelerating the science of SCD therapies-is a cure possible? Jama. 322:921. https:\/\/doi.org\/10.1001\/jama.2019.11419","journal-title":"Jama."},{"issue":"3","key":"4233_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/pbc.22792","volume":"56","author":"JA Wolfson","year":"2011","unstructured":"Wolfson JA, Schrager SM, Coates TD, Kipke MD (2011) Sickle-cell disease in California: a population-based description of emergency department utilization. Pediatr Blood Cancer 56(3):413\u2013419","journal-title":"Pediatr Blood Cancer"},{"issue":"5 Suppl","key":"4233_CR15","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/j.acap.2014.02.008","volume":"14","author":"S Reeves","year":"2014","unstructured":"Reeves S, Garcia E, Kleyn M, Housey M, Stottlemyer R, Lyon-Callo S, Dombkowski KJ (2014) Identifying sickle cell disease cases using administrative claims. Acad Pediatr 14(5 Suppl):S61\u2013S67. https:\/\/doi.org\/10.1016\/j.acap.2014.02.008","journal-title":"Acad Pediatr"},{"issue":"4","key":"4233_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.29245\/2572-9411\/2017\/4.1124","volume":"2","author":"AB Snyder","year":"2017","unstructured":"Snyder AB, Lane PA, Zhou M, Paulukonis ST, Hulihan MM (2017) The accuracy of hospital ICD-9-CM codes for determining sickle cell disease genotype. J Rare Dis Res Treatment 2(4):39\u201345","journal-title":"J Rare Dis Res Treatment"},{"issue":"10","key":"4233_CR17","doi-asserted-by":"publisher","first-page":"a011783","DOI":"10.1101\/cshperspect.a011783","volume":"3","author":"GR Serjeant","year":"2013","unstructured":"Serjeant GR (2013) The natural history of sickle cell disease. Cold Spring Harbor Perspect Med 3(10):a011783. https:\/\/doi.org\/10.1101\/cshperspect.a011783","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"16","key":"4233_CR18","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1001\/jama.2015.3075","volume":"313","author":"N Stettler","year":"2015","unstructured":"Stettler N, McKiernan CM, Adejoro OO, Walczak NB (2015) Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. Jama 313(16):1671\u20131672","journal-title":"Jama"},{"key":"4233_CR19","doi-asserted-by":"crossref","unstructured":"Kleinbaum DG, Klein M (2012) Extension of the Cox proportional hazards model for time-dependent variables. In: Survival analysis. Springer, pp. 241\u2013288","DOI":"10.1007\/978-1-4419-6646-9_6"},{"issue":"13","key":"4233_CR20","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jama.2010.378","volume":"303","author":"DC Brousseau","year":"2010","unstructured":"Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA (2010) Acute care utilization and rehospitalizations for sickle cell disease. Jama 303(13):1288\u20131294","journal-title":"Jama"},{"key":"4233_CR21","doi-asserted-by":"crossref","unstructured":"Shah N, Bhor M, Xie L, Paulose J, Yuce H (2019) Sickle cell disease complications: prevalence and resource utilization. BioRxiv:577189","DOI":"10.1101\/577189"},{"issue":"10","key":"4233_CR22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/ajh.22106","volume":"86","author":"BG Hemker","year":"2011","unstructured":"Hemker BG, Brousseau DC, Yan K, Hoffmann RG, Panepinto JA (2011) When children with sickle-cell disease become adults: lack of outpatient care leads to increased use of the emergency department. Am J Hematol 86(10):863\u2013865. https:\/\/doi.org\/10.1002\/ajh.22106","journal-title":"Am J Hematol"},{"issue":"1","key":"4233_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pedhc.2012.11.001","volume":"28","author":"J Chang","year":"2014","unstructured":"Chang J, Freed GL, Prosser LA, Patel I, Erickson SR, Bagozzi RP, Balkrishnan R (2014) Comparisons of health care utilization outcomes in children with asthma enrolled in private insurance plans versus Medicaid. J Pediatr Health Care 28(1):71\u201379. https:\/\/doi.org\/10.1016\/j.pedhc.2012.11.001","journal-title":"J Pediatr Health Care"},{"issue":"3","key":"4233_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/art.21991","volume":"55","author":"HI Brunner","year":"2006","unstructured":"Brunner HI, Taylor J, Britto MT, Corcoran MS, Kramer SL, Melson PG, Kotagal UR, Graham TB, Passo MH (2006) Differences in disease outcomes between Medicaid and privately insured children: possible health disparities in juvenile rheumatoid arthritis. Arthritis Rheum 55(3):378\u2013384. https:\/\/doi.org\/10.1002\/art.21991","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4233_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/pbc.22069","volume":"53","author":"M Mvundura","year":"2009","unstructured":"Mvundura M, Amendah D, Kavanagh PL, Sprinz PG, Grosse SD (2009) Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer 53(4):642\u2013646. https:\/\/doi.org\/10.1002\/pbc.22069","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"4233_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ajh.21880","volume":"86","author":"M Treadwell","year":"2011","unstructured":"Treadwell M, Telfair J, Gibson RW, Johnson S, Osunkwo I (2011) Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol 86(1):116\u2013120","journal-title":"Am J Hematol"},{"key":"4233_CR27","unstructured":"Manwani D, Davidson L, Silver E, Chhabra R, Minniti C, Rastogi D, Doyle M, Morrone KA, Stein R, Oyeku S (2017) An intensive transition navigator intervention improves transition readiness to adult care in youth with sickle cell disease. Am Soc Hematology"},{"key":"4233_CR28","doi-asserted-by":"crossref","unstructured":"Saulsberry AC, Podila PS, Anderson S, Hodges JR, Porter J, Hankins JS (2018) Efficacy of a health care transition program for patients with sickle cell disease. Am Soc Hematology","DOI":"10.1182\/blood-2018-99-113535"},{"key":"4233_CR29","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/pds.4860","volume":"28","author":"ZT Su","year":"2019","unstructured":"Su ZT, Segal JB, Lanzkron S, Ogunsile FJ (2019) National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017. Pharmacoepidemiol Drug Saf 28:1246\u20131250. https:\/\/doi.org\/10.1002\/pds.4860","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"4233_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ajh.21968","volume":"86","author":"SD Candrilli","year":"2011","unstructured":"Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R (2011) Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 86(3):273\u2013277. https:\/\/doi.org\/10.1002\/ajh.21968","journal-title":"Am J Hematol"},{"issue":"2","key":"4233_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26774","volume":"65","author":"R Colombatti","year":"2018","unstructured":"Colombatti R, Palazzi G, Masera N, Notarangelo LD, Bonetti E, Samperi P, Barone A, Perrotta S, Facchini E, Miano M (2018) Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: results of a national multicenter survey. Pediatr Blood Cancer 65(2):e26774","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"4233_CR32","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3324\/haematol.2016.153791","volume":"102","author":"P Maitra","year":"2017","unstructured":"Maitra P, Caughey M, Robinson L, Desai PC, Jones S, Nouraie M, Gladwin MT, Hinderliter A, Cai J, Ataga KI (2017) Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica 102(4):626\u2013636","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04233-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T01:44:58Z","timestamp":1630460698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04233-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4233"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04233-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"17 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RJD has received unrestricted research grants from Merck and Bayer for unrelated projects. SS is consultant to WHISCON, LLC and to Aetion, Inc., a software manufacturer of which he also owns equity. He is principal investigator of investigator-initiated grants to the Brigham and Women\u2019s Hospital from Genentech and Boehringer Ingelheim unrelated to the topic of this study. AM and DG are employees of and own stock in Vertex Pharmaceuticals. KM is an employee of CRISPR Therapeutics. RB is a Consultant to Vertex Pharmaceuticals Inc. and owner of a Bohn Epidemiology, a consulting company that works with pharmaceutical and biotechnology companies. There are no conflicts of interest to disclose for the other co-authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted using de-identified data and the protocol was approved by the Brigham and Women\u2019s Hospital Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Programming codes are available from the corresponding upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"No work for other companies is related to this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}